|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
In addition, we found a correlation between <i>PLA2G5</i> gene expression and both epithelial-mesenchymal transition and the isocitrate dehydrogenase 1 mutation status in these tumors.
|
31114356 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The candidate genes located at amplified regions of chromosomes or low-level gain regions such as PLA2G5 (1p36-p34), COL11A1 (1p21), KCNK2 (1q41), S100A3 (1q21), ENAH (1q42.12), RGS1 (1q31), KCNH1 (1q32-q41), INSIG2 (2q14.1), FGF12 (3q28), TRIO (5p15.2), RNASEN (5p15.2), FGF10 (5p13-p12), EDN1(6p24.1-p22.3), SULF1 (8q13.2-13.3), TLR4 (9q32-q33), TNC (9q33), NTRK2 (9q22.1), CD44 (11p13), NCAM1 (11q23.1), TRIM29 (11q22-q23), PAK1 (11q13-q14) and RAB27A (15q15-q21.1), are found to be associated with cellular migration and proliferation, tumor cell metastasis and invasion, anchorage independent growth and inhibition of apoptosis.
|
20083228 |
2010 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrate the association of the PLA2G5 rs11573191 polymorphism with premature CAD.
|
24959594 |
2014 |
|
Coronary Artery Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.
|
24563418 |
2014 |
|
Coronary Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.
|
24563418 |
2014 |
|
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This novel approach for single-nucleotide polymorphism selection for this modified Mendelian randomization analysis showed no association between rs525380 (the lead single-nucleotide polymorphism for PLA2G5 expression, a surrogate for sPLA2-V levels) and CHD events.
|
24563418 |
2014 |
|
Eosinophilia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Unexpectedly, while adoptive transfer of bone marrow-derived (BM)-macrophages restored ILC2 activation and eosinophilia in Alternaria-exposed Pla2g5-null mice, exogenous IL-33 did not.
|
29346348 |
2018 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The immunohistochemistry of the 82 glioma tissues further confirmed that PLA2G5 protein expression was dependent on the WHO glioma grade.
|
31114356 |
2019 |
|
Hypertensive disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
PLA2G5 polymorphisms were in linkage disequilibrium and the CGA haplotype was associated with increased risk of premature CAD (OR = 1.49, P = 0.0023) and with hypertension in these patients (OR = 1.75, P = 0.0072).
|
24959594 |
2014 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The candidate genes located at amplified regions of chromosomes or low-level gain regions such as PLA2G5 (1p36-p34), COL11A1 (1p21), KCNK2 (1q41), S100A3 (1q21), ENAH (1q42.12), RGS1 (1q31), KCNH1 (1q32-q41), INSIG2 (2q14.1), FGF12 (3q28), TRIO (5p15.2), RNASEN (5p15.2), FGF10 (5p13-p12), EDN1(6p24.1-p22.3), SULF1 (8q13.2-13.3), TLR4 (9q32-q33), TNC (9q33), NTRK2 (9q22.1), CD44 (11p13), NCAM1 (11q23.1), TRIM29 (11q22-q23), PAK1 (11q13-q14) and RAB27A (15q15-q21.1), are found to be associated with cellular migration and proliferation, tumor cell metastasis and invasion, anchorage independent growth and inhibition of apoptosis.
|
20083228 |
2010 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
As such, PLA2G5 tipped the immune balance toward an M2 state, thereby counteracting adipose tissue inflammation, insulin resistance, hyperlipidemia, and obesity.
|
24910243 |
2014 |
|
Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Group V phospholipase A<sub>2</sub> (Pla2g5) is a lipid-generating enzyme necessary for macrophage effector functions in pulmonary inflammation.
|
29346348 |
2018 |
|
Schizophrenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
An association between the BanI polymorphism of the PLA2G4A gene for calcium-dependent phospholipase A2 and plasma glucose levels among females with schizophrenia.
|
30103930 |
2018 |
|
Neurodegenerative Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
In contrast, no loss of function or common (minor-allele frequency>0.05%) nonsynonymous PLA2G5 variants have been previously reported (EVS, dbSNP, 1000 Genomes Project) or were detected in an internal database of 224 exomes (from subjects with adult onset neurodegenerative disease and without a diagnosis of ophthalmic disease).
|
22137173 |
2011 |
|
Carcinogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
A calcium-dependent phospholipase A2 (cPLA2) expression is regulated by MIG-6 during endometrial tumorigenesis.
|
30773264 |
2019 |
|
Adenomatous polyp of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
DNA sequence analysis demonstrated that alterations of PLA2G2A, as well as related genes PLA2G2C and PLA2G5, were evenly distributed between three classes of AAPC subjects: those with small, intermediate, and large numbers of adenomatous colonic polyps.
|
8640784 |
1996 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The candidate genes located at amplified regions of chromosomes or low-level gain regions such as PLA2G5 (1p36-p34), COL11A1 (1p21), KCNK2 (1q41), S100A3 (1q21), ENAH (1q42.12), RGS1 (1q31), KCNH1 (1q32-q41), INSIG2 (2q14.1), FGF12 (3q28), TRIO (5p15.2), RNASEN (5p15.2), FGF10 (5p13-p12), EDN1(6p24.1-p22.3), SULF1 (8q13.2-13.3), TLR4 (9q32-q33), TNC (9q33), NTRK2 (9q22.1), CD44 (11p13), NCAM1 (11q23.1), TRIM29 (11q22-q23), PAK1 (11q13-q14) and RAB27A (15q15-q21.1), are found to be associated with cellular migration and proliferation, tumor cell metastasis and invasion, anchorage independent growth and inhibition of apoptosis.
|
20083228 |
2010 |
|
Eosinophilic disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Unexpectedly, while adoptive transfer of bone marrow-derived (BM)-macrophages restored ILC2 activation and eosinophilia in Alternaria-exposed Pla2g5-null mice, exogenous IL-33 did not.
|
29346348 |
2018 |
|
Premature coronary artery atherosclerosis
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The (G>A) rs11573191 polymorphism of PLA2G5 gene is associated with premature coronary artery disease in the Mexican Mestizo population: the genetics of atherosclerotic disease Mexican study.
|
24959594 |
2014 |
|
Pneumonitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Group V phospholipase A<sub>2</sub> (Pla2g5) is a lipid-generating enzyme necessary for macrophage effector functions in pulmonary inflammation.
|
29346348 |
2018 |
|
Fleck Retina, Familial Benign
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Fleck Retina, Familial Benign
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
C-reactive protein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease.
|
31070471 |
2019 |
|
Infection
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease.
|
15377291 |
2004 |